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Definitions
ACS was defined as typical angina with abnormal cardiac biomarkers and/or ECG evidence of ischemia. Definite ST was defined according to the Academic Research Consortium (ARC) 7 angiographic criteria in all cases; presence of a thrombus originating in the stent or in the segment 5-mm proximal or distal to the stent and the presence of at least one of the following criteria within a 48-h window of time: acute ischemic symptoms at rest, new ischemic ECG changes and/or typical rise and fall in cardiac biomarkers. The thrombus could be occlusive or not. 7 Depending on the timing, ST was categorized as early (within 30 days) and late (between 30 days and 1 year); no cases of ST were observed beyond 1 year (very late ST).
Interventional Procedure and Adjunctive Medical Therapy
Interventions were performed according to current practice guidelines for PCI 8 via the femoral approach; 6Fr catheters were used, and patients were anticoagulated during PCI with 50-70 UI/kg of unfractionated heparin. The diameter of the implanted stent was selected by the operator to obtain a stent diameter/reference vessel diameter ratio between 1 and 1.1. All patients received aspirin (250 mg) and were given a 600-mg loading dose of clopidogrel before the angioplasty. The use of thromboaspiration catheters and glycoprotein GIIb/IIIa inhibitors was at the discretion of the operator. Aspirin was continued indefinitely, with a dose of 100-250 mg daily, and clopidogrel was continued for 1 year with a daily dose of 75 mg. Cessation of aspirin and of clopidogrel before 1 year was considered as being premature.
Angiographic Analysis
Angiograms were examined by 2 experienced interventional cardiologist who were blinded to the patients' outcomes. The modified American College of Cardiology (ACC)/American Heart Association (AHA) lesion morphology criteria 8 were used to qualitatively evaluate the angiograms; type B2 and C lesions were categorized as complex. Calcifications were identified as readily apparent radio-opacities. The length of the lesions (L) and the percentage stenosis (by quantitative coronary angiography) were specified. The coronary flow grade was determined according to TIMI classification. 9 The thrombus was defined as a filling defect surrounded by contrast in multiple projections when nonocclusive and as TIMI flow 0 or 1 within the stent or in proximity when occlusive. protein (CRP) levels >20 mg/L during PCI, lower left ventricular ejection fraction and more often had a rescue PCI; they also prematurely discontinued treatment with clopidogrel and/or aspirin more frequently.
Statistical Analysis
As far as the angiographic characteristics are concerned, patients with ST had smaller reference vessel diameters with more complex lesions and they were more likely to have a visible thrombus and TIMI flow grade <2 before PCI.
Identification of ST Risk Factors
Clinical and angiographic factors associated in the univariable analysis with the occurrence of ST are depicted respectively in Figures 2,3. Tables 3-5 show the independent predictors of ST, early ST and late ST with associated adjusted hazard ratios (HR) and 95% confidence intervals (CI). The determinants that were independently associated with the occurrence of ST were related to patient behavior, such as resumption of smoking and premature cessation of clopidogrel, or to angiographic characteristics, such as a reference vessel diameter <2.8 mm, a TIMI flow grade before PCI <2 and the presence of a visible intracoronary thrombus. Also, periprocedural fever was identified as an independent predictor of ST. Early ST represented 55% of all cases of ST; the independent determinants associated with its occurrence were fever during PCI, CRP level >30 mg/L and the presence of a thrombus. Concerning late ST, identified independent predictors were premature discontinuation of clopidogrel, resumption of smoking, rescue PCI, age <55 years and a reference vessel diameter <2.8 mm.
Discussion
This study involved a homogeneous patient population as regards the indication of coronary angioplasty, as well as the type of stent used for the index PCI. Indeed, the mechanisms involved in ST depend on these 2 elements and its predictive factors could be different.
In most of the main registries, 10-15 ACS appears to be the elective condition in the occurrence of ST. In the present single-center study of 611 consecutive Tunisian patients who underwent stenting for ACS and were followed up for a median period of 16 months, the cumulative incidence of definite ST was 3.5%. Two-thirds of the patients had STEMI, but the difference in ST incidence according to clinical presentation did not reach statistical significance (STEMI: 3.9%, NSTEMI: 2.9%, UA: 2.4%). The cumulative incidence of ST in patients with STEMI undergoing emergency PCI was as high as 9.2%, which could be explained by the low rate of use of glycoprotein IIb/IIIa inhibitors in these patients.
In the TRITON-TIMI 38 trial, 16 3,224 ACS patients were treated with BMS and received aspirin and clopidogrel poststenting. In that group the incidence of definite ST was 2.13% throughout a follow-up of 15 months. In a post-randomization analysis from the angiographic substudy of the ACUITY Trial, Aoki et al demonstrated an early definite ST rate of 0.9% in moderate to high-risk ACS patients, with similar frequencies in the BMS and DES groups and in different anticoagulation regimen groups. 2 In their cohort study, Kukreja et al 17 demonstrated in patients with ACS (n=3,485) after a median followup of 3.8 years, a definite ST rate of 2.5% vs. 1.0% in patients with stable angina (HR 2.8; 95%CI 1.72-4.56). In their ACS patients who received a BMS, the rate of definite ST was 2%. As in our study, the incidence of ST in STEMI (2.8%) and UA/NSTEMI (2.3%) was not significantly different. Beinart et al 3 found in 1,202 ACS patients an incidence of early ST of 2.5% and they demonstrated its graduated occurrence from UA to STEMI (UA: 0%, NSTEMI: 1.4%, UA/NSTEMI: 0.9%, STEMI: 3.9%, P<0.05); STEMI was the most potent predictor of ST (odds ratio 6.3; 95%CI 2.1-18, P=0.0008) and, as in our study, the incidence of ST was particularly high in STEMI patients who underwent primary PCI (5.2%). The higher incidence of ST demonstrated in our single-center routine practice experience in comparison with other ACS studies might be related to the higher frequency of STEMI patients. Our findings are primarily in agreement with the STEMI studies. In the Harmonizing Outcomes with Revascularization and Stents in AMI (HORIZONS-AMI) trial, 18 in which stents were implanted in 3,202 patients presenting with STEMI and undergoing primary PCI, the rate of definite ST at 2 years was 3.6% in the BMS group despite exclusion of unstable and complicated patients. In the Single High Dose Bolus Tirofiban and Sirolimus Eluting Stent vs. Abciximab and Bare Metal Stent in Myocardial Infarction (STRATEGY) randomized singlecenter study, 19 the ST rate after 5 years' follow-up was 7.9% in the BMS group. TYPHOON 20 was also a multicenter, prospectively randomized trial comparing sirolimus-eluting stents (n=355) with BMS (n=357) in primary PCI for STEMI; it demonstrated 1-year ST rates of 3.4% and 3.6%, respectively (P=1.00) in this selected population. Similar findings were reported by Park et al. 21 These rates contrast with those from studies excluding STEMI patients and emergency PCI, such Tables 1,2 . Tables 1,3 . Stent Thrombosis in ACS as the Li et al 22 cohort study of UA/NSTEMI patients where the 1-year incidence of ST in BMS (n=366) was 0.5% (similar to that of DES (n=1,493): 0.7%). Primary BMS stenting during STEMI has been recognized as an independent predictor of late stent malapposition 23 the incidence of which in this setting was 11.5% vs. 4.3% for elective stenting (P=0.007). Late stent malapposition after emergency stenting seems to be related to the intraluminal thrombus burden, and it is likely caused by thrombus compression or displacement by the struts of the stent in the acute phase, with thrombus resolution in the long term. In Sianos et al's 24 angiographic study, analysis of 812 patients showed that patients with large thrombus burden (vessel diameter ≥2) had a poorer procedural outcome when considering the final TIMI flow grade, myocardial blush grade, thrombus removal, no reflow and distal embolization, and that a large thrombus burden was the strongest independent predictor (HR 8.73; 95%CI 3.39-22.47, P<0.001) of infarct-related artery ST, the 2-year incidence of which was 8.2% in this group vs. 1.3% in the small thrombus burden group (P=0.001). In our study, even if the thrombus burden was not scored, the presence of a visible thrombus on angiography was an independent predictor of ST and early ST. The paradoxical trend to a higher incidence of ST in patients treated with thromboaspiration catheters and glycoprotein IIb/IIIa inhibitors in our population is because these therapies were indicated when a large thrombus burden was visualized on angiograms.
In accordance with other studies, 25,26 small arteries were predictive factors of ST, probably because of coronary flow limitation and a larger quantity of metal by unit of surface.
Our study results emphasize the role of inflammation in the occurrence of ST, and we identified a threshold preprocedural CRP level of 30 mg/L as an independent predictor of this event, whereas in other studies even a minimal increase in the CRP level resulted in an increased risk of ST. 27,28 High-sensitivity CRP could better reflect vascular wall inflammation. 29 Park et al suggested the incorporation of CRP into a model with patient, lesion, and procedural factors to increase the C statistic for the prediction of ST and major adverse cardiac events. 27 Interestingly, in our study the presence of fever was also a predictor of ST.
By thwarting the effect of inflammation in patients with increased CRP levels, 30 statin therapy could have a protective role.
The discontinuation of anticoagulant therapy has been demonstrated to expose the patient to the risk of ST, 31,32 and our study confirms the necessity of continuing clopidogrel therapy for 12 months in ACS patients treated with BMS, as its cessation before 1 year was, in our experience, the strongest predictor of late ST (HR 11.97; 95%CI 2.39-59.98). As with medication adherence, smoking cessation is a pillar of secondary prevention. These failures, probably because of insufficient educational measures, increased the risk of ST in our patients.
Age less than 55 years increased the risk of late ST occurrence in this study. In some studies, 24,33 younger age was identified as an independent predictor of ST. However, this factor remains controversial and not found by all studies. The other main clinical predictors of ST, such as diabetes 34 and renal failure, 35 could not be identified in our study, which might be related to more selective indications for stenting in these patients in whom mean lesion and stent lengths were shorter than in other patients.
Finally, in our study with a median follow-up of 16 months, we did not observe any case of very late ST; indeed, very late BMS thrombosis is a rare complication even in patients with ACS and few cases have been reported, 36 mainly related to atherosclerosis progression and progressive neointimal proliferation. 37 
Study Limitations
We restricted the definition of ST to ACR-definite ST, which was mainly based on angiographic confirmation; this could underestimate the real incidence of this complication. This cohort study did not have the power of randomized trials to identify risk factors, but it reflects our routine clinical experience. The duration of follow-up was probably insufficient to make conclusions concerning very late ST.
Conclusions
In addition to angiographic and inflammatory determinants, factors related to patient behavior (medication cessation, resumption of smoking) exposed patients to a higher risk of ST in this study. Their improvement by better patient education may reduce this risk.
